Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMWX7N)

Drug Name

J147 Drug Info

Synonyms

j147; J-147; 1146963-51-0; UNII-Z41H3C5BT9; 1807913-16-1; Z41H3C5BT9; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazide; N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N-((E)-(3-methoxyphenyl)methylideneamino)acetamide; Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide; Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; N-(2,4-DIMETHYLPHENYL)-2,2,2-TRIFLUORO-N'-[(1E)-(3-METHOXYPHENYL)METHYLIDENE]ACETOHYDRAZIDE; CHEMBL2387144; SCHEMBL12995834; SCHEMBL21294999; 2,2,2-Trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide; CHEBI:192601; HYMZAYGFKNNHDN-SSDVNMTOSA-N; DTXSID501045787; HMS3886O17; EX-A2235; MFCD25976644; s5269; AKOS024458485; CCG-268030; CS-3688; DB13957; AC-35232; AS-16718; HY-13779; A894156; (E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylidene]acetohydrazide; N-(2,4-dimethylphenyl)-2,2,2-triluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]

Cross-matching ID

PubChem CID: 25229652
TTD Drug ID: DMMWX7N

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ATP synthase (ATPS)	TTX1KNQ	NOUNIPROTAC	inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03838185) A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers. U.S.National Institutes of Health.
2	Broadening the horizon: Integrative pharmacophore-based and cheminformatics screening of novel chemical modulators of mitochondria ATP synthase towards interventive Alzheimer's disease therapy. Med Hypotheses. 2019 Sep;130:109277.